PE20151065A1 - Novedosos derivados de bencimidazol como antagonistas de ep4 - Google Patents
Novedosos derivados de bencimidazol como antagonistas de ep4Info
- Publication number
- PE20151065A1 PE20151065A1 PE2015000750A PE2015000750A PE20151065A1 PE 20151065 A1 PE20151065 A1 PE 20151065A1 PE 2015000750 A PE2015000750 A PE 2015000750A PE 2015000750 A PE2015000750 A PE 2015000750A PE 20151065 A1 PE20151065 A1 PE 20151065A1
- Authority
- PE
- Peru
- Prior art keywords
- benzimidazole derivatives
- novelty
- antagonists
- preparation
- indications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
La presente invencion se refiere a novedosos derivados de bencimidazol de la formula general (I), a procedimientos para su preparacion, asi como su uso para la preparacion de agentes farmaceuticos para el tratamiento de enfermedades e indicaciones que estan relacionadas con el receptor EP4
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195849 | 2012-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151065A1 true PE20151065A1 (es) | 2015-08-19 |
Family
ID=47325927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000750A PE20151065A1 (es) | 2012-12-06 | 2013-12-03 | Novedosos derivados de bencimidazol como antagonistas de ep4 |
Country Status (41)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014134267A1 (en) | 2013-02-27 | 2014-09-04 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| KR20160060660A (ko) | 2013-10-01 | 2016-05-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 친화성 크로마토그래피를 위한 및 치료제의 반감기를 연장시키기 위한 화합물 |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| DK3466949T3 (da) * | 2013-12-24 | 2021-03-15 | Bristol Myers Squibb Co | Tricyklisk forbindelse som anticancermidler |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CN104326937B (zh) * | 2014-09-03 | 2016-08-24 | 天津市肿瘤研究所 | 抗肿瘤化合物及其医药用途 |
| NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| AU2017371200B2 (en) | 2016-12-09 | 2021-05-06 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2018162562A1 (en) * | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
| PT3625224T (pt) | 2017-05-18 | 2021-10-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-substituídos |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| AU2018269666B2 (en) | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| KR20200097293A (ko) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN113527206B (zh) * | 2020-04-17 | 2022-12-30 | 上海中泽医药科技有限公司 | 一种苯并氮杂环类化合物、其制备方法及用途 |
| WO2022102731A1 (ja) | 2020-11-13 | 2022-05-19 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
| KR20230099093A (ko) * | 2021-12-27 | 2023-07-04 | 에이치케이이노엔 주식회사 | 벤즈이미다졸 유도체의 제조방법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
| ATE442147T1 (de) | 2000-01-18 | 2009-09-15 | Bayer Schering Pharma Ag | Pharmazeutische zubereitung enthaltend drospirenon |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| NZ535748A (en) | 2002-04-12 | 2007-06-29 | Pfizer | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases |
| EP1532119A2 (en) * | 2002-07-31 | 2005-05-25 | Euro-Celtique S.A. | Aryl substituted benzimidazoles and their use as sodium channel blockers |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| JP2006508145A (ja) | 2002-11-15 | 2006-03-09 | テイボテク・フアーマシユーチカルズ・リミテツド | 抗感染化合物としての置換インドールピリジニウム |
| US6949564B2 (en) | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
| DK1603893T3 (da) | 2003-01-29 | 2008-09-08 | Asterand Uk Ltd | EP4 -Receptorantagonister |
| AU2004226179A1 (en) | 2003-04-03 | 2004-10-14 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the GABA-a receptor complex |
| TW200512147A (en) | 2003-07-25 | 2005-04-01 | Black Clawson Converting Machinery Inc | Method and apparatus for splicing webs |
| BRPI0414130B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
| US20090036495A1 (en) | 2004-04-20 | 2009-02-05 | Pfizer, Inc. | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists |
| US20060160799A1 (en) | 2004-04-23 | 2006-07-20 | Alekshun Michael N | Transcription factor modulating compounds and methods of use thereof |
| WO2005105733A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| WO2006077366A1 (en) * | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| AU2007242018B2 (en) | 2006-04-24 | 2012-07-19 | Merck Canada Inc. | Indole amide derivatives as EP4 receptor antagonists |
| US7732447B2 (en) * | 2006-06-22 | 2010-06-08 | Cephalon, Inc. | Fused [d]pyridazin-7-ones |
| GB0614066D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
| US8969394B2 (en) | 2006-08-11 | 2015-03-03 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
| AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| AU2008284303A1 (en) | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Process for making thiophene carboxamide derivative |
| CA2733247C (en) | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| WO2010117639A2 (en) | 2009-03-31 | 2010-10-14 | The Texas A&M University System | Inhibition of prostglandin e2 receptors for the treatment of endometriosis |
| US20110059962A1 (en) | 2009-04-22 | 2011-03-10 | Alekshun Michael N | Transcription factor modulating compounds and methods of use thereof |
| EP2538978B1 (en) * | 2010-02-22 | 2016-09-07 | RaQualia Pharma Inc. | Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
-
2013
- 2013-03-12 UA UAA201506493A patent/UA115576C2/uk unknown
- 2013-12-03 MA MA38146A patent/MA38146B1/fr unknown
- 2013-12-03 DK DK13798684.0T patent/DK2928884T3/en active
- 2013-12-03 WO PCT/EP2013/075309 patent/WO2014086739A1/de active Application Filing
- 2013-12-03 RS RS20170790A patent/RS56121B1/sr unknown
- 2013-12-03 EP EP13798684.0A patent/EP2928884B1/de active Active
- 2013-12-03 AP AP2015008463A patent/AP3862A/en active
- 2013-12-03 PT PT137986840T patent/PT2928884T/pt unknown
- 2013-12-03 ME MEP-2017-181A patent/ME02950B/me unknown
- 2013-12-03 BR BR112015012555-7A patent/BR112015012555B1/pt active IP Right Grant
- 2013-12-03 CN CN201380063594.4A patent/CN104854098B/zh active Active
- 2013-12-03 PE PE2015000750A patent/PE20151065A1/es active IP Right Grant
- 2013-12-03 MX MX2015007135A patent/MX2015007135A/es active IP Right Grant
- 2013-12-03 MY MYPI2015701808A patent/MY175272A/en unknown
- 2013-12-03 EA EA201591087A patent/EA028830B1/ru not_active IP Right Cessation
- 2013-12-03 PL PL13798684T patent/PL2928884T3/pl unknown
- 2013-12-03 JP JP2015545771A patent/JP6367822B2/ja active Active
- 2013-12-03 LT LTEP13798684.0T patent/LT2928884T/lt unknown
- 2013-12-03 AU AU2013354226A patent/AU2013354226B2/en active Active
- 2013-12-03 NZ NZ707825A patent/NZ707825A/en unknown
- 2013-12-03 SI SI201330742T patent/SI2928884T1/sl unknown
- 2013-12-03 CA CA2893630A patent/CA2893630C/en active Active
- 2013-12-03 KR KR1020157017666A patent/KR20150092248A/ko active IP Right Grant
- 2013-12-03 US US14/649,896 patent/US9708311B2/en active Active
- 2013-12-03 ES ES13798684.0T patent/ES2637738T3/es active Active
- 2013-12-04 JO JOP/2013/0349A patent/JO3431B1/ar active
- 2013-12-06 UY UY0001035177A patent/UY35177A/es unknown
- 2013-12-06 AR ARP130104542A patent/AR093840A1/es unknown
- 2013-12-06 TW TW102144979A patent/TWI613198B/zh not_active IP Right Cessation
-
2015
- 2015-05-27 IL IL239026A patent/IL239026A0/en active IP Right Grant
- 2015-06-04 CL CL2015001508A patent/CL2015001508A1/es unknown
- 2015-06-04 CU CU2015000056A patent/CU20150056A7/es unknown
- 2015-06-05 TN TNP2015000250A patent/TN2015000250A1/fr unknown
- 2015-06-05 PH PH12015501289A patent/PH12015501289B1/en unknown
- 2015-06-05 CR CR20150296A patent/CR20150296A/es unknown
- 2015-06-05 GT GT201500138A patent/GT201500138A/es unknown
- 2015-06-05 EC ECIEPI201522555A patent/ECSP15022555A/es unknown
- 2015-06-05 NI NI201500077A patent/NI201500077A/es unknown
- 2015-10-29 HK HK15110717.4A patent/HK1210139A1/xx unknown
-
2017
- 2017-08-04 HR HRP20171200TT patent/HRP20171200T1/hr unknown
- 2017-08-10 CY CY20171100862T patent/CY1119200T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151065A1 (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
| CR20150370A (es) | Compuestos antivirales | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
| PE20151067A1 (es) | Inhibidores de autotaxina | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| ECSP11011517A (es) | Compuestos antivirales | |
| GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| GT201300122A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| CR20130671A (es) | Antagonistas de trpv4 | |
| NI201500050A (es) | Benzamidas | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| NI201300125A (es) | Derivados de 2 - amino - 3 - ( imidazol - 2 - il ) - piridin - 4 - ona y su uso como inhibidores de cinasa del receptor vegf. | |
| GT201200066A (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CU20140058A7 (es) | Nuevos 2h-indizoles como antagonistas del receptor ep-2 | |
| CU20140007A7 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a | |
| BR112015001515A2 (pt) | compostos terapêuticos | |
| CU20100047A7 (es) | Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3 | |
| CU20100045A7 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3 | |
| CU20110003A7 (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |